The COVID-19 from Neurological Overview

Acar, Türkan; Demirel, Esra; Afşar, Nazire; Akcali, Aylin; Demir, Gülşen Akman; Alagöz, Aybala Neslihan; Mengi, Tuğçe; Arsava, Ethem Murat; Ayta, Semih; Bebek, Nerses; Bılgıç, Başar; Boz, Cavit; Çakar, Arman; Çelebisoy, Neşe; Çevik, Mehmet Uğur; Delen, Firuze; Tekçe, Hacer Durmuş; Ekmekçi, Hakan; Elmalı, Ayşe Deniz; Erdinç, Oğuz Osman; Erdoğan, Füsun; Eren, Fettah; Ergün, Ufuk; Parman, Yeşim; Gümüş, Haluk; Algin, Demet Ilhan; Karabudak, Rana; Karadaş, Ömer; Yıldız, Özlem; Koç, Emine; Adapınar, Demet Özbabalık; Özdemi̇r, Atilla Özcan; Öztürk, Şerefnur; Kocaman, Ayşe Sağduyu; Sahin, Şevki; Topçuoğlu, Esen Saka; Şener, Özden; Tezer, F. İrsel; Toğrol, Erdem; Tokçaer, Ayşe Bora; Topçuoğlu, Mehmet Akif; Tuncer, Neşe; Uca, Ali Ulvi; Uluç, Kayıhan; Yaka, Erdem; Yon, Mehmet Ilker

doi:10.4274/tnd.2020.73669

Cited by 14 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronavirus outbreak (SARS-CoV-2) emerged in Wuhan province of China towards the end of 2019 and it was announced as a pandemic on March 11, 2020, when the first case was reported in Turkey (Acar et al, 2020;WHO,2020). The spread of the coronavirus influenced the daily routines, social and economic lives of the people and this pandemic period in which even healthy people were under a great risk, has become more traumatic for elderly people and for those who have chronic disorders (Salari et al, 2020) It has been reported that people with multiple sclerosis (PwMS) can be in the risk group, as this is a chronic disease, and these patients use medications that affect the immune system.…”

Section: Introductionmentioning

confidence: 99%

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic

Yeni

Tülek

Terzı

2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic

Yeni

Tülek

Terzı

2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…With the support of their relatives, patients should continue exercises such as remembering loved ones, place-time-person orientation as well as bearing in mind (25). In this regard, patients are recommended to spend more time and share more things with their relatives (26). After the onset of the outbreak in France, a part of hospitalization units was dedicated to COVID-19 positive patients, as acute Alzheimer unit and behavior unit.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Sürecinde Deliryum Olgu Sunumu ve Demansın Literatür Taraması

Sönmez

Aktürk

Saçmacı

2020

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Coronavirus directly infects the nervous system and may cause the course of the existing neurological disease to get worse in those with a chronic neurological disease. People with dementia, which is the most common chronic neurological disease over 65 years old, have serious difficulties in terms of follow-up and treatment of their diseases in the social isolation process. However, due to the risk factors caused by coronavirus disease 2019 (COVID-19), it has become easier for them to go into delirium. These risk factors can be listed as social isolation, inactivity, intense stress, as well as direct invasion of the virus to the central nervous system, the effect of inflammatory cytokines, the effect of sedative drugs used and the effect that develops secondary to other accompanying diseases. This paper provides an assessment regarding the problems experienced by dementia patients in the pandemic process, and their solutions, accompanied by a case presentation.

show abstract

“…However, in the case of COVID-19, neurological diseases affecting PNS and muscles are less common. They include Guillain-Barré syndrome, Miller Fisher syndrome, cranial polyneuritis, and rare cases of viral myopathy accompanied by rhabdomyolysis [60].…”

Section: Complicationsmentioning

confidence: 99%

From asymptomatic to critical illness: decoding various clinical stages of COVID-19

Çelik¹,

Öztürk²

2021

Turk J Med Sci

View full text Add to dashboard Cite

The clinical course of COVID-19 is variable, with clinical manifestation ranging from 81% mild course to 14% severe course along with 5% critical course in patients. The asymptomatic course is reported to potentially range between 20% and 70% (avg. 33%). A more severe course is seen in the elderly, those with various chronic diseases, and the immunosuppressed, where the case fatality rate is higher in these risk groups. The disease progresses with various symptoms, such as fever, cough, shortness of breath, malaise, myalgia, taste and smell disorders, diarrhea, sore throat, headache, and conjunctivitis. The disease begins with shortness of breath, indicative of lung damage, after an average of 7 to 10 days, and progresses in ARDS, sepsis, and septic shock. Some patients quickly enter shortness of breath, while others gradually develop shortness of breath and chest tightness and burning. The risk factors for a poor prognosis are age, comorbidities, and changes in laboratory tests. Secondary bacterial and fungal infections frequently develop with steroids and immunosuppressants, especially in the intensive care unit. Frequent complications in hospitalized patients include pneumonia (75%), ARDS (15%), acute renal failure (9%), and acute liver injury (19%). An increased incidence of heart damage is observed, including acute heart failure, arrhythmias, and myocarditis. Of the patients hospitalized due to COVID-19, 10%-25% present with prothrombotic coagulopathy, resulting in venous and arterial thromboembolic events. The most common extrapulmonary symptom is neuropsychiatric involvement, frequently accompanied by insomnia, an impediment to remembering, and an altered state of consciousness. During the course of COVID-19, patients undergo some pathological changes (severe lymphopenia, high levels of C-reactive protein, D-dimer, ferritin, etc.) depending on the condition and exposure level of the affected systems as shown by various laboratory tests. The relevant tests are the guiding elements of risk assessment, clinical monitoring, disease severity, and prognosis setting and therapy decisionmaking processes.

show abstract

The COVID-19 from Neurological Overview

Cited by 14 publications

References 0 publications

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic

COVID-19 Sürecinde Deliryum Olgu Sunumu ve Demansın Literatür Taraması

From asymptomatic to critical illness: decoding various clinical stages of COVID-19

Contact Info

Product

Resources

About